Patent intelligence · US
US 9125822
Particle for medical use and process for producing the same
Particle for medical use and process for producing the same
Patent details — US 9125822
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 8, 2015
- Expiration
- Sep 3, 2035
- Applicant
- SUMITOMO BAKELITE CO., LTD.
- Claims
- 9
- CPC classes
- A61K, A61K9/1676
Quick answer
US 9125822 (Particle for medical use and process for producing the same) is held by SUMITOMO BAKELITE CO., LTD.. Status: granted. Granted Sep 8, 2015. Expires Sep 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUMITOMO BAKELITE CO., LTD.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K9/1676
More from SUMITOMO BAKELITE CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 9125822?
US 9125822 (Particle for medical use and process for producing the same) is held by SUMITOMO BAKELITE CO., LTD.. Status: granted. Granted Sep 8, 2015. Expires Sep 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9125822?
SUMITOMO BAKELITE CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 9125822 expire?
Our index shows an expiration date of Sep 3, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.